期刊文献+

Smac基因在增强乳腺癌细胞株MCF-7对环磷酰胺和多柔比星敏感性中的作用

Smac playing vital role in enhancing the sensitivity of cyclophosphamide and doxorubicin in breast cancer MCF-7 cell line
原文传递
导出
摘要 目的研究Smac基因在乳腺癌细胞株MCF-7中对化疗药物环磷酰胺(CTX)和多柔比星(DOX)化疗敏感性的影响。方法分别用化疗药物CTX、DOX及二者联合处理乳腺癌细胞株MCF-7,用四甲基偶氮唑蓝(MTT)法分析细胞生存率,吖啶橙染色和Ho.33342/PI双染法检测细胞凋亡,RT-PCR和Western blotting检测Smac的mRNA和蛋白水平,并进一步分析促凋亡蛋白活性caspase3和活性caspase9的表达变化。结果CTX、DOX及二者联合应用降低了MCF-7细胞的生存率,并且呈浓度依赖性。4.0 μg/ml CTX、0.2 μg/ml DOX及2.0 μg/ml CTX联合0.1 μg/ml DOX处理细胞48 h后,细胞生存率分别是(52.90±8.78)%、(53.35±6.29)%和(34.19±5.43)%。与4.0 μg/ml CTX、0.2 μg/ml DOX相比,联合用药有更强的抑制细胞生长作用(t=9.051,P=0.014;t=9.074,P=0.014)。2.0 μg/ml CTX联合0.1 μg/ml DOX处理细胞48 h后,Smac的mRNA和蛋白水平分别为7.47±0.82和4.13±0.36,4.0 μg/ml CTX组分别为3.27±0.40(t=-50.120,P=0.000)和2.28±0.27(t=-42.588,P=0.000),0.2 μg/ml DOX组分别为3.34±0.62(t=-46.233,P=0.000)和2.45±0.40(t=-39.541,P=0.000),与单一用药相比,联合用药后Smac在mRNA和蛋白水平上都明显升高。同时发现活性caspase-3和活性caspase-9的蛋白表达水平也明显升高。结论Smac在提高乳腺癌细胞株MCF-7对CTX和DOX化疗敏感性中发挥了重要作用。 ObjectiveTo investigate the influence of Smac to the chemosensitivity of cyclophosphamide (CTX) and doxorubicin (DOX) in MCF-7 cells. MethodsMCF-7 cells were exposed to CTX, DOX and the combination of both. 3-(4,5-dimethyl-2-thiazoly)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to estimate the cell viability. Apoptosis was measured by acridine orange staining and Ho.33342/PI double staining. The mRNA and protein expressions of Smac were determined by RTPCR and Western blotting. The study also analyzed the changes of proapoptotic proteins active caspase3 and active caspase9. ResultsCTX, DOX and the combination of both drugs reduced the cell survival rates in a concentrationdependent manner. The cell viability after being treated with 4.0 μg/ml CTX or 0.2 μg/ml DOX or 2.0 μg/ml CTX and 0.1 μg/ml DOX for 48 hours was (52.90±8.78)%, (53.35±6.29)% and (34.19±5.43)%, respectively. The drug combination developed a stronger inhibitory effect compared to the single drugs (t=9.051, P=0.014; t=9.074, P=0.014). The Smac mRNA and protein levels in 2.0 μg/ml CTX and 0.1 μg/ml DOX group were 7.47±0.82 and 4.13±0.36, which were higher than those in 4.0 μg/ml CTX group (3.27±0.40 and 2.28±0.27; t=-50.120, P=0.000; t=-42.588,P=0.000) and 0.2 μg/ml DOX group (3.34±0.62 and 2.45±0.40; t=-46.233, P=0.000; t=-39.541, P=0.000). Furthermore, proapoptotic proteins active caspase-3 and active caspase9 increased activity was confirmed by Western blotting. ConclusionSmac plays a vital role in enhancing the sensitivity of chemotherapeutic drugs CTX and DOX in MCF-7 cell line.
出处 《国际肿瘤学杂志》 CAS 2015年第12期881-885,共5页 Journal of International Oncology
基金 山东省科技发展计划(2014GSF118095)
关键词 乳腺肿瘤 环磷酰胺 多柔比星 细胞凋亡 SMAC Breast neoplasms Cyclophosphamide Doxorubicin Apoptosis Smac
  • 相关文献

参考文献13

  • 1Goldner B, Behrendt CE, Schoellhammer HF, et al. Incidence of inflammatory breast cancer in women, 1992—2009, United States[J].Ann Surg Oncol.2014, 21(4):1267-1270.
  • 2徐武夷,杨文.乳腺癌治疗进展[J].海军总医院学报,2011,24(1):29-33. 被引量:29
  • 3Rudolf E, Rudolf K, Cervinka M. Selenium activates p53 and p38 pathways and induces caspaseindependent cell death in cervical cancer cells[J].Cell Biol Toxicol.2008, 24(2):123-141.
  • 4Gradzka I. Mechanisms and regulation of the programmed cell death[J]. Postepy Biochem, 2006, 52(2): 157-165.
  • 5Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochromecdepedent caspase activations by eliminating IAP inhibition[J].Cell.2000, 102(1):33-42.
  • 6Ghavami S, Asoodeh A, Klonisch T, et al. Brevinin2R(1) semiselectively kills cancer cells by a distinct mechanism, which involves the lysosomalmitochondrial death pathway[J].J Cell Mol Med.2008, 12(3):1005-1022.
  • 7Li L, Jiang AC, Dong P, et al. MDR1/Pgp and VEGF synergistically enhance the invasion of Hep2 cells with multidrug resistance induced by taxol[J].Ann Surg Oncol.2009, 16(5):1421-1428.
  • 8Dai Y, Liu M, Tang W, et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis[J].Clin Cancer Res.2008, 14(23):7701-7710.
  • 9Korga A, Korobowicz E, Dudka J. Role of mitochondrial protein Smac in regulation of apoptotic pathways[J]. Pol Merkur Lekarski, 2006, 20(119): 573-576.
  • 10MartinezRuiz G, Maldonado V, CeballosCancino G, et al. Role of Smac/DIABLO in cancer progression[J].J Exp Clin Cancer Res.2008, 27:48-.

二级参考文献22

  • 1Veronesi U, Cascinellin, Marianin L, et al. Twenty-year follow up of a randomized study comparing breast-con- serving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med,2002,347(16):1227-1232.
  • 2Fisher B, Anderson S, Bryant J, et al. Twenty-year fol- low-up of a randomized trail comparing total mastecto- my,lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16) : 1223-1241.
  • 3van Dongen JA, Voogd AC, Fentiman IS, et al. Long- term results of a randomized trail comparing breast- conserving therapy with mastectomy .. European Organ- ization for Research and Treatment of Cancer 10801 trial[J]. J Natl Cancer Inst,2000,92(14) :1143-1150.
  • 4Veronesi U, Paganelli G, Viale G, et aL A randomized comparison of sentinel-node biopsy with routine axilla- ry dissection in breast cancer [J]. N Engl J Med,2003, 349(6) :546-553.
  • 5Prosnitz LR, Marks LB. Partial breast irradiation= a cautionary note[J]. Int J Radiat Oncol Biol Phys,2006, 65(2) :319-321.
  • 6Goyal A, Mansel RE. Recent advances in sentinel lymph node biopsy for breast cancer[J]. Curt Opin On- col,2008,20(6) :621-626.
  • 7Huang EH, Tucker Sir, Strom EA, et al. Postmastecto- my radiation improves local regional control and sur- vival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy [ J ]. J Clin Oncol, 2004, 22 ( 23 ) : 4691- 4699.
  • 8Vogel CL, Cobleigh MA, Tripathy D, et al. First line hereeptin monotherapy in metastatic breast eancer[J]. Oneology,2001,61 Suppl 2:37 -42.
  • 9Arpino G,Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family., molecular mechanism and clini- cal implications for endocrine therapy resistance[J]. Endocr Rev,2008,29(2) :217-233.
  • 10Bonadonna G, Motiterni A, Zambetti M,et al. 30 years 'follow up of randomised studies of adjuvant CMF in operable breast cancer : cohort study [ J]. BMJ, 2005, 330(7485) :217.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部